# Brilaroxazine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/brilaroxazine

> The next catalyst for brilaroxazine, sponsored by REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH), is its trial start, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for brilaroxazine?

The next catalyst for brilaroxazine, sponsored by REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH), is its trial start, 1H 2027. SEC Form 10-Q: "We plan to initiate patient enrollment in the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in the first half of 2027, subject to additional financing." [Calendar and source filings](https://sec-api.dev/pdufa/brilaroxazine)

Source: SEC Form 10-Q, accession 0001437749-26-036648, https://www.sec.gov/Archives/edgar/data/1742927/000143774926036648/rvph20260930_10q.htm (retrieved 2026-11-14). Last confirmed 2026-11-13. Cite: https://sec-api.dev/pdufa/brilaroxazine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | brilaroxazine |
| Codes |  |
| Sponsor | REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) https://sec-api.dev/companies/rvph/catalysts |
| Indications | [schizophrenia](https://sec-api.dev/indications/schizophrenia) |
| Modality |  |
| FDA designations | orphan |

## Timeline

### October 30, 2023: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: schizophrenia.
- First seen 2024-11-14, last confirmed 2026-03-19.
- SEC Form 10-Q (accession 0001437749-25-034827): "On October 30, 2023, we announced positive topline results and successful completion of our pivotal RECOVER-1 Trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin dopamine signaling modulator in adults with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774925034827/rvph20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-026967): "On October 30, 2023, we announced positive topline results and successful completion of our pivotal RECOVER-1 Trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin dopamine signaling modulator in adults with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774925026967/rvph20250630_10q.htm
- SEC Form 10-Q (accession 0001437749-25-017191): "On October 30, 2023, we announced positive topline results and successful completion of our pivotal RECOVER-1 Trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin dopamine signaling modulator in adults with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-010791): "On October 30, 2023, we announced positive topline results and successful completion of our pivotal RECOVER-1 Trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin dopamine signaling modulator in adults with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774925010791/rvph20241231_10k.htm
- SEC Form 10-Q (accession 0001437749-24-035375): "On October 30, 2023, we announced positive topline results and successful completion of our pivotal RECOVER-1 Trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin dopamine signaling modulator in adults with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774924035375/rvph20240930_10q.htm
- SEC prospectus (424B) (accession 0001437749-25-029530): "On October 30, 2023, we announced positive topline results and successful completion of our pivotal RECOVER-1 Trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin dopamine signaling modulator in adults with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774925029530/rvph20250919_424b5.htm
- SEC prospectus (424B) (accession 0001437749-26-009062): "On October 30, 2023, we announced positive topline results of the RECOVER Trial." https://www.sec.gov/Archives/edgar/data/1742927/000143774926009062/rvph20260319_424b5.htm
- SEC prospectus (424B) (accession 0001437749-26-008843): "On October 30, 2023, we announced positive topline results of the RECOVER Trial." https://www.sec.gov/Archives/edgar/data/1742927/000143774926008843/rvph20260317_424b5.htm
- SEC prospectus (424B) (accession 0001437749-26-009062): "On October 30, 2023, we announced positive topline results and successful completion of its pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin dopamine signaling modulator in adults with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774926009062/rvph20260319_424b5.htm
- SEC prospectus (424B) (accession 0001437749-26-008843): "On October 30, 2023, we announced positive topline results and successful completion of its pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin dopamine signaling modulator in adults with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774926008843/rvph20260317_424b5.htm
- SEC Form 10-Q (accession 0001437749-25-034827): "On October 30, 2023, we announced positive topline results from our Phase 3 RECOVER 1 trial (the "RECOVER-1 Trial"), which is a global Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of brilaroxazine in approximately 400 patients with acute schizophrenia compared to placebo." https://www.sec.gov/Archives/edgar/data/1742927/000143774925034827/rvph20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-026967): "On October 30, 2023, we announced positive topline results from our Phase 3 RECOVER 1 trial (the "RECOVER-1 Trial"), which is a global Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of brilaroxazine in approximately 400 patients with acute schizophrenia compared to placebo." https://www.sec.gov/Archives/edgar/data/1742927/000143774925026967/rvph20250630_10q.htm

### Dec 2024: topline data readout

- Status: scheduled. Date confidence: month.
- First seen 2024-11-12, last confirmed 2024-11-14.
- SEC Form 10-Q (accession 0001437749-24-035375): "We expect to report topline data from our OLE Trial in December 2024, with the OLE Trial expected to complete in Q-1 2025, and we expect to initiate the registrational RECOVER-2 Trial in the first quarter of 2025, subject to receipt of additional financing, with completion anticipated in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1742927/000143774924035375/rvph20240930_10q.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-035391): "- Topline data from OLE trial expected in December 2024 -" https://www.sec.gov/Archives/edgar/data/1742927/000143774924035391/ex_748171.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-035391): "Importantly, we expect topline data from the OLE trial in December 2024." https://www.sec.gov/Archives/edgar/data/1742927/000143774924035391/ex_748171.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-035391): "Topline data from 1-year OLE trial expected in December 2024" https://www.sec.gov/Archives/edgar/data/1742927/000143774924035391/ex_748171.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-034338): "- Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 -" https://www.sec.gov/Archives/edgar/data/1742927/000143774924034338/ex_746295.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-034338): "We now expect to report topline 12-month long-term safety and efficacy data in December of 2024."" https://www.sec.gov/Archives/edgar/data/1742927/000143774924034338/ex_746295.htm
- SEC Form 10-Q (accession 0001437749-24-035375): "-OLE Trial topline data readout expected in December 2024, with OLE Trial expected to complete in Q1-2025" https://www.sec.gov/Archives/edgar/data/1742927/000143774924035375/rvph20240930_10q.htm

### December 16, 2024: interim data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: schizophrenia.
- First seen 2024-12-16, last confirmed 2026-11-13.
- SEC Form 10-Q (accession 0001437749-25-034827): "On December 16, 2024, we announced positive preliminary topline data from, and on June 2, 2025, we announced a positive full dataset and successful completion of, our Phase 3 RECOVER open label extension (the "OLE" or the "OLE Trial") a 1-year study evaluating the long-term safety, tolerability and efficacy of brilaroxazine in patients with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774925034827/rvph20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-026967): "On December 16, 2024, we announced positive preliminary topline data from, and on June 2, 2025, we announced a positive full dataset and successful completion of, our Phase 3 RECOVER open label extension (the "OLE" or the "OLE Trial") 1-year study evaluating the long-term safety, tolerability and efficacy of brilaroxazine in patients with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774925026967/rvph20250630_10q.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-037520): "Cupertino, Calif., December 16, 2024 - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced positive preliminary topline data for the open-label extension (OLE) portion of the Company's ongoing Phase 3 RECOVER study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774924037520/ex_757662.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-010191): "Positive preliminary topline data for the OLE portion of the Company's ongoing Phase 3 RECOVER study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia announced (December 2024)" https://www.sec.gov/Archives/edgar/data/1742927/000143774925010191/ex_796258.htm
- SEC prospectus (424B) (accession 0001437749-25-029530): "On December 16, 2024, we announced positive preliminary topline data from, and on June 2, 2025, we announced a positive full dataset and successful completion of, our Phase 3 RECOVER open label extension (the "OLE" or the "OLE Trial") 1-year study evaluating the long-term safety, tolerability and efficacy of brilaroxazine in patients with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774925029530/rvph20250919_424b5.htm
- SEC Form 10-Q (accession 0001437749-25-017191): "On December 16, 2024, we announced positive preliminary topline data from the open label extension (the "OLE" or the "OLE Trial") portion of the RECOVER Trial evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm
- SEC Form 10-Q (accession 0001437749-25-017191): "On December 16, 2024, we announced positive preliminary topline data from our OLE evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-010791): "On December 16, 2024, we announced positive preliminary topline data from our OLE evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774925010791/rvph20241231_10k.htm
- SEC Form 8-K (accession 0001437749-24-037520): "On December 16, 2024, the Company announced positive preliminary topline data from its OLE evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia." https://www.sec.gov/Archives/edgar/data/1742927/000143774924037520/rvph20241215_8k.htm
- SEC Form 10-Q (accession 0001437749-25-017191): "We reported positive preliminary topline data from the OLE in December 2024, with full data analysis of the OLE trial including long-term safety, tolerability and efficacy, as well as biomarker data, expected in Q2-2025." https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-010791): "We reported positive preliminary topline data from the OLE in December 2024, with the OLE expected to complete in Q2-2025, and we expect to initiate the registrational RECOVER-2 Trial in mid-2025, subject to receipt of additional financing, with topline readout anticipated in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1742927/000143774925010791/rvph20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-010791): "We reported positive preliminary topline data from the OLE in December 2024, with the OLE expected to complete in Q2-2025, and we expect to initiate the registrational RECOVER-2 Trial in the second quarter of 2025, subject to receipt of additional financing, with topline readout anticipated in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1742927/000143774925010791/rvph20241231_10k.htm

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-12-23, last confirmed 2026-05-13.
- SEC Form 8-K (accession 0001437749-25-038602): "Subject to sufficient financing, Reviva may also initiate a Phase 3 trial of brilaroxazine for negative symptoms or bipolar disorder (the "Negative Symptoms/Bipolar Trial") in the second quarter of 2026, and based on this timeline of intended trial initiation, the Company plans for the Negative Symptoms/Bipolar Trial data to be available in the third quarter of 2027, with a potential supplemental New Drug Application (sNDA) targeted for filing in the fourth quarter of 2027 for potential approval in the fourth quarter of 2028." https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/rvph20251216_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-010140): "Plans to initiate brilaroxazine second registrational Phase 3 trial (RECOVER-2) for schizophrenia in mid-2026, with trial-related activities for RECOVER-2 planned to start in Q2-2026 and patient enrollment in the U.S. planned to begin in Q3-2026." https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/ex_937921.htm
- SEC Form 8-K (accession 0001437749-25-038602): "Subject to sufficient financing, Reviva plans to initiate the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in the first half of 2026, and based on this timeline of intended trial initiation, the Company plans for the RECOVER-2 Trial data to be available in the second quarter of 2027, with a potential NDA targeted for filing in the fourth quarter of 2027, and potential approval in the fourth quarter of 2028." https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/rvph20251216_8k.htm
- SEC Form 10-Q (accession 0001437749-26-016762): "We plan to initiate trial related activities for the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in Q2-2026 and begin patient enrollment in the United States in Q3-2026." https://www.sec.gov/Archives/edgar/data/1742927/000143774926016762/rvph20260331_10q.htm
- SEC Form 10-Q (accession 0001437749-26-016762): "* We plan to initiate trial related activities for the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in Q2-2026 and begin patient enrollment in the United States in Q3-2026." https://www.sec.gov/Archives/edgar/data/1742927/000143774926016762/rvph20260331_10q.htm
- SEC Form 10-K (accession 0001437749-26-010126): "We plan to initiate trial related activities for the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in Q2-2026 and begin patient enrollment in the United States in Q3-2026." https://www.sec.gov/Archives/edgar/data/1742927/000143774926010126/rvph20251231_10k.htm
- SEC Form 10-K (accession 0001437749-26-010126): "* We plan to initiate trial related activities for the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in Q2-2026 and begin patient enrollment in the United States in Q3-2026." https://www.sec.gov/Archives/edgar/data/1742927/000143774926010126/rvph20251231_10k.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-038602): "Subject to sufficient financing, Reviva plans to initiate the RECOVER-2 Phase 3 trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/ex_902002.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-010140): "- Initiation of RECOVER-2 registrational trial planned in mid-2026 -" https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/ex_937921.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-038602): "Initiation of RECOVER-2 registrational trial planned in H1 2026, subject to sufficient financing" https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/ex_902002.htm

### Q3 2026: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-04-03, last confirmed 2025-05-15.
- SEC Form 10-Q (accession 0001437749-25-017191): "We expect to initiate the registrational RECOVER-2 Trial in mid-2025, subject to receipt of additional financing, with topline readout anticipated in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm
- SEC Form 10-Q (accession 0001437749-25-017191): "-Phase 3 RECOVER-2 Trial expected initiation in mid-2025, subject to receipt of additional financing, with topline readout anticipated in the third quarter of 2026" https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-010791): "-Phase 3 RECOVER-2 Trial expected initiation in mid-2025, subject to receipt of additional financing, with topline readout anticipated in the third quarter of 2026" https://www.sec.gov/Archives/edgar/data/1742927/000143774925010791/rvph20241231_10k.htm

### Q4 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-04-03, last confirmed 2025-04-03.
- SEC Form 10-K (accession 0001437749-25-010791): "These data from our brilaroxazine clinical development plan will potentially support the planned NDA submission to the FDA in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1742927/000143774925010791/rvph20241231_10k.htm

### 1H 2027: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-08-12, last confirmed 2026-11-13.
- SEC Form 10-Q (accession 0001437749-26-036648): "We plan to initiate patient enrollment in the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in the first half of 2027, subject to additional financing." https://www.sec.gov/Archives/edgar/data/1742927/000143774926036648/rvph20260930_10q.htm
- SEC Form 10-Q (accession 0001437749-26-036648): "* We plan to initiate patient enrollment in the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in the first half of 2027, subject to additional financing." https://www.sec.gov/Archives/edgar/data/1742927/000143774926036648/rvph20260930_10q.htm
- SEC Form 10-Q (accession 0001437749-26-027358): "We plan to initiate patient enrollment in the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1742927/000143774926027358/rvph20260630_10q.htm
- SEC Form 10-Q (accession 0001437749-26-027358): "* We plan to initiate patient enrollment in the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1742927/000143774926027358/rvph20260630_10q.htm

## Same indication

- [Direclidine](https://sec-api.dev/pdufa/direclidine) (NBIX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/brilaroxazine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Brilaroxazine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/brilaroxazine

```bibtex
@misc{secapidev_pdufa_brilaroxazine_20261116,
  title        = {Brilaroxazine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/brilaroxazine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_brilaroxazine_20261116","title":"Brilaroxazine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/brilaroxazine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
